-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Gael Forterre MBA
Chief Commercial Officer
Gael is the Chief Commercial Officer of Volition joining the team in 2021.
![Gael Forterre](https://volition.com/wp-content/uploads/2023/11/team-gael-forterre.jpg)
Gael is the Chief Commercial Officer of Volition joining the team in 2021. He is focused on building a strong commercialization plan and team to drive the extensive range of products developed using the Nu.Q™ platform.
Gael has extensive experience investing in and scaling fast growing companies, most recently as CEO of Path Inc. He is currently a non-executive board member of Integrated Wellness Holdings.
Gael started his career as a hedge fund analyst in Paris and worked in a number of investment banking and more recently executive roles for over fifteen plus years. Gael received a master’s in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.
“I am delighted to work with such a passionate team to drive commercialization of the product pipeline.”
![Gael Forterre](https://volition.com/wp-content/uploads/2023/11/team-gael-forterre.jpg)
Gael Forterre MBA
Chief Commercial Officer